This is a plain language summary of an article originally published in the journal Blood Pressure Monitoring. Vibegron is a medicine that was approved by the US Food and Drug Administration (also called FDA) in 2020 for treatment of overactive bladder, a condition that causes a frequent and urgent need to urinate. This study took place before the medicine was approved to look at whether vibegron affects blood pressure or heart rateThis Plain Language Summary of Publication article from Future Cardiology describes a study that looked at a medication called vibegron and it’s effectiveness and safety in people with overactive bladder.

Please visit Future Medicine using the link to read the article.

The original article on which this summary is based is called ‘Effects of vibegron on ambulatory blood pressure in patients with overactive bladder: results from a double-blind, placebo-controlled trial.’ It was published in Blood Pressure Monitoring. 

Please visit Blood Pressure Monitoring using the link to read the article.